1. 首页
  2. 产品
  3. Signaling Pathways 信号通路
  4. New Products | 新产品
  5. NEW1
  6. New1

Cephalexin hydrochloride hydrate

别名: Cephalexin hydrochloride; Keftab; Cephalexin HCl; 105879-42-3; Cefalexin hydrochloride; LY061188; UNII-6VJE5G3D98; 6VJE5G3D98;
目录号: V17920 纯度: ≥98%
COA 产品数据 产品说明书 SDS
头孢氨苄（Cefalexin）HCl一水合物是一种口服生物活性的新型半合成头孢菌素抗生素（抗生素），具有广泛的抗菌谱。
Cephalexin hydrochloride hydrate CAS号: 105879-42-3
产品类别: New1
产品仅用于科学研究，不针对患者销售
规格 价格
50mg
大包装询价
020-31522723 sales@invivochem.cn

Other Forms of Cephalexin hydrochloride hydrate:

  • 头孢氨苄
  • 头孢氨苄盐酸盐
  • 头孢氨苄(一水物)
  • L-赖氨酸头孢氨苄
点击了解更多
InvivoChem产品被CNS等顶刊论文引用
产品描述
头孢氨苄（Cefalexin）HCl一水合物是一种口服生物活性的新型半合成头孢菌素抗生素（抗生素），具有广泛的抗菌谱。头孢氨苄 (Cefalexin) HCl 一水合物对多种革兰氏阳性 (Gram+) 和革兰氏阴性 (Gram-) 细菌具有抗菌作用。头孢氨苄 (Cefalexin) HCl 一水合物以青霉素结合蛋白 (PBP) 为靶点，抑制细菌细胞壁组装。盐酸头孢氨苄（头孢氨苄）一水合物可用于肺炎、链球菌性咽喉炎、细菌性心内膜炎等的研究/研究。
生物活性&实验参考方法
靶点
Bacterial cell wall synthesis; penicillin binding proteins (PBPs); cephalosporin antibiotic
体外研究 (In Vitro)
盐酸头孢氨苄一水合物 (10 μg/mL) 可使一种称为青霉素结合蛋白 (PBP) 的酶失活，该酶会干扰聚合物肽聚糖 (PG) 的合成 [1]。盐酸头孢氨苄 (Cefalexin) 一水合物的 MIC 值为 2、2、2、2、4、4.4 和 5.7 μg/mL，可抑制多种革兰氏阳性和革兰氏阴性细菌。它们是 Proteus rettgeri、Alcaligenes sp. 和 Edwardsiella tarda [2]。
体内研究 (In Vivo)
就抗菌活性而言，患有细菌感染的雄性 Swiss-Webster 小鼠对盐酸头孢氨苄（头孢氨苄一水合物）（0-50 mg/kg；口服；3.5 小时）反应良好 [2]。
酶活实验
青霉素和相关的β -内酰胺构成了我们最古老和最广泛使用的抗生素疗法之一。人们早就知道，这些药物的靶点是一种叫做青霉素结合蛋白(PBPs)的酶，这种酶负责构建细菌细胞壁。研究了靶抑制的下游后果，以及它们如何导致这些重要药物的致命作用，我们证明了β -内酰胺不仅仅是像通常认为的那样抑制PBPs。相反，它们诱导目标生物合成机制发生毒性故障，涉及细胞壁合成和降解的无效循环，从而耗尽细胞资源并增强其杀伤活性。这种作用模式的表征还揭示了细胞壁基质中裂解键的酶的质量控制功能。因此，这些结果提供了对细胞壁组装机制的深入了解，并建议如何最好地干预未来抗生素开发的过程。[1]
动物实验
Animal/Disease Models: Bacterially infected male Swiss-Webster mice [2]
Doses: 0-50 mg/kg
Route of Administration: po (po (oral gavage)) 3.5 hrs (hrs (hours))
Experimental Results: Against Streptococcus pyogenes, Streptococcus pneumoniae, Staphylococcus aureus and several Antimicrobial activity against Gram-negative bacteria in mice.
药代性质 (ADME/PK)
Absorption
Well absorbed from the upper gastrointestinal tract with nearly 100% oral bioavailability. Cephalexin is not absorbed in the stomach but is absorbed in the upper intestine. Patients taking 250mg of cephalexin reach a maximum plasma concentration of 7.7mcg/mL and patients taking 500mg reach 12.3mcg/mL.

Route of Elimination
Cephalexin is over 90% excreted in the urine after 6 hours by glomerular filtration and tubular secretion with a mean urinary recovery of 99.3%. Cephalexin is unchanged in the urine.

Volume of Distribution
5.2-5.8L.

Clearance
Clearance from one subject was 376mL/min.

LESS THAN 10 TO 15%...IS BOUND TO PLASMA PROTEIN, & PLASMA DRUG CONCN FALL RAPIDLY... MORE THAN 90%...IS EXCRETED UNALTERED IN URINE WITHIN 6 HR, PRIMARILY BY RENAL TUBULAR SECRETION. ...THERAPEUTICALLY EFFECTIVE CONCN ARE STILL ACHIEVED IN URINE OF PT WITH DECR RENAL FUNCTION.

CEPHALEXIN...IS WELL ABSORBED FROM GI TRACT. PEAK PLASMA CONCN, REACHED @ ABOUT 1 HR AFTER INGESTION OF DRUG, ARE APPROX 9 & 18 UG/ML AFTER ORAL DOSES OF 250 & 500 MG, RESPECTIVELY. INGESTION OF FOOD MAY DELAY ABSORPTION.

BOTH ABSORPTION & EXCRETION OF CEPHALEXIN ARE IMPAIRED IN NEW-BORN INFANTS, WHERE 24-HR URINARY RECOVERY OF ANTIBIOTIC ACCOUNTED FOR 5-66% OF DAILY ORAL DOSE.
Metabolism / Metabolites
Cephalexin is not metabolized in the body.
Biological Half-Life
The half life of cephalexin is 49.5 minutes in a fasted state and 76.5 minutes with food though these times were not significantly different in the study. The serum half-life of cephalexin is 0.5-1.2 hr in adults with normal renal function. The serum half-life of the drug is reported to be about 5 hr in neonates and 2.5 hr in children 3-12 mo of age. In one study, the serum half-life was 7.7 hr in adults with creatinine clearances of 9.2 ml/min and 13.9 hr in adults with creatinine clearances of 4 ml/min.
Protein Binding
Cephalexin is 10-15% bound to serum proteins including serum albumin.
毒性/毒理 (Toxicokinetics/TK)
Effects During Pregnancy and Lactation
◉ Summary of Use during Lactation
Limited information indicates that maternal cephalexin produces low levels in milk that are usually not expected to cause adverse effects in breastfed infants. Cephalexin is an alternative for the treatment of mastitis. Occasionally disruption of the infant's gastrointestinal flora, resulting in diarrhea or thrush have been reported with cephalosporins, but these effects have not been adequately evaluated. A rare case of a severe allergic reaction occurred in an infant previously exposed to intravenous cefazolin whose mother began taking cephalexin while breastfeeding. Cephalexin is acceptable in nursing mothers.

◉ Effects in Breastfed Infants
In a prospective follow-up study, 7 nursing mothers reported taking cephalexin (dosage not specified). Two mothers reported diarrhea in their infants. No rashes or candidiasis were reported among the exposed infants.
A prospective, controlled study asked mothers who called an information service about adverse reactions experience by their breastfed infants. One of 11 cephalexin-exposed infants reportedly developed diarrhea during maternal cephalexin therapy.
A woman received intravenous cephalothin 1 g every 6 hours for 3 days. Her breastfed infant had a green liquid stool, severe diarrhea, discomfort and crying. The mother's drug regimen was then changed to oral cephalexin 500 mg plus oral probenecid 500 mg 4 times daily for another 16 days. The infant continued to have diarrhea during this time. The authors rated the diarrhea as probably related to cephalexin in milk.
A 4-month-old infant was treated with intravenous cefazolin for a urinary tract infection. Nine days after being discharged and cefazolin discontinuation, the infant developed a blistering rash over most of the body that was diagnosed as toxic epidermal necrolysis (TEN). The infant was being breastfed (extent unspecified) by his mother who had begun cephalexin 2 days prior to the onset of symptoms. A lymphocyte transformation test performed 4 weeks after treatment for TEN was completed found sensitization to both cefazolin and cephalexin. The infant's reaction was probably caused by cephalexin in breastmilk after initial sensitization and subsequent cross-reaction to cefazolin.

◉ Effects on Lactation and Breastmilk
Relevant published information was not found as of the revision date.
View More

◈ What is cephalexin?
Cephalexin is an antibiotic medication that has been used to treat infections such as Staphylococcus aureus (Staph) and Escherichia coli (E. coli). Some brand names for cephalexin are Keflex® and Keftab®.Sometimes when people find out they are pregnant, they think about changing how they take their medication, or stopping their medication altogether. However, it is important to talk with your healthcare providers before making any changes to how you take your medication. Your healthcare providers can talk with you about the benefits of treating your condition and the risks of untreated illness during pregnancy.Having certain infections (such as a Staph or E. coli infection )during pregnancy can increase the chance for pregnancy-related problems or infections in a newborn baby. MotherToBaby has fact sheets on Staph and E. coli infections here: https://mothertobaby.org/fact-sheets/staphylococcus-aureus-pregnancy/ and https://mothertobaby.org/fact-sheets/e-coli-pregnancy/.

◈ I take cephalexin. Can it make it harder for me to get pregnant?
Studies have not been done in humans to see if cephalexin can make it harder to get pregnant. In animal studies, cephalexin did not affect fertility (ability to get pregnant).

◈ Does taking cephalexin increase the chance of miscarriage?
Miscarriage is common and can occur in any pregnancy for many different reasons. In a study of 262 people who took cephalexin during pregnancy, there was no increase in miscarriages compared to a similar group of people who did not take cephalexin.

◈ Does taking cephalexin increase the chance of birth defects?
Every pregnancy starts out with a 3-5% chance of having a birth defect. This is called the background risk. Information on the use of cephalexin in pregnancy is limited. In a study of 262 people who took cephalexin during pregnancy, there was no increased chance for birth defects above the background risk.

◈ Does taking cephalexin in pregnancy increase the chance of other pregnancy-related problems?
Studies have not been done to see if cephalexin increases the chance for pregnancy-related problems such as preterm delivery (birth before week 37) or low birth weight (weighing less than 5 pounds, 8 ounces [2500 grams] at birth).

◈ Does taking cephalexin in pregnancy affect future behavior or learning for the child?
Studies have not been done to see if cephalexin can cause behavior or learning issues for the child.

◈ Breastfeeding while taking cephalexin:
Cephalexin gets into breast milk in small amounts. In reports of 20 babies exposed to cephalexin through breast milk, 4 had diarrhea. There is one report of a baby getting a rash after being breastfed, due to a sensitivity to cephalexin. If you suspect the baby has any symptoms (such as diarrhea or rash), contact the child’s healthcare provider. Be sure to talk to your healthcare provider about all your breastfeeding questions.

◈ If a male takes cephalexin, could it affect fertility or increase the chance of birth defects?
Studies have not been done to see if cephalexin could affect male fertility (ability to get partner pregnant) or increase the chance of birth defects above the background risk. Some infections, such as Staph or E.coli, might affect male fertility. In general, exposures that fathers or sperm donors have are unlikely to increase risks to a pregnancy. For more information, please see the MotherToBaby fact sheet Paternal Exposures at https://mothertobaby.org/fact-sheets/paternal-exposures-pregnancy/.

参考文献

[1]. Beta-lactam antibiotics induce a lethal malfunctioning of the bacterial cell wall synthesis machinery. Cell. 2014 Dec 4;159(6):1300-11.

[2]. Cefadroxil, a new broad-spectrum cephalosporin. Antimicrob Agents Chemother. 1977 Feb;11(2):324-30.
其他信息
Cephalexin Hydrochloride is the hydrochloride salt form of cephalexin, a beta-lactam, first-generation cephalosporin antibiotic with bactericidal activity. Cephalexin hydrochloride binds to and inactivates penicillin-binding proteins (PBP) located on the inner membrane of the bacterial cell wall. PBPs participate in the terminal stages of assembling the bacterial cell wall, and in reshaping the cell wall during cell division. Inactivation of PBPs interferes with the cross-linkage of peptidoglycan chains necessary for bacterial cell wall strength and rigidity. This results in the weakening of the bacterial cell wall and causes cell lysis.
A semisynthetic cephalosporin antibiotic with antimicrobial activity similar to that of CEPHALORIDINE or CEPHALOTHIN, but somewhat less potent. It is effective against both gram-positive and gram-negative organisms.
See also: Cephalexin (is salt form of).
*注: 文献方法仅供参考, InvivoChem并未独立验证这些方法的准确性
化学信息 & 存储运输条件
分子式
C16H17N3O4S.CLH.H2O
分子量
347.3889
精确质量
401.081
元素分析
C, 47.82; H, 5.02; Cl, 8.82; N, 10.46; O, 19.91; S, 7.98
CAS号
105879-42-3
相关CAS号
Cephalexin;15686-71-2;Cephalexin hydrochloride;59695-59-9;Cephalexin monohydrate;23325-78-2;Cephalexin (lysine);53950-14-4
PubChem CID
62979
外观&性状
Typically exists as solid at room temperature
密度
1.5g/cm3
沸点
727.4ºC at 760mmHg
闪点
393.7ºC
蒸汽压
3.27E-22mmHg at 25°C
折射率
1.699
LogP
2.661
tPSA
150.75
氢键供体(HBD)数目
5
氢键受体(HBA)数目
7
可旋转键数目(RBC)
4
重原子数目
26
分子复杂度/Complexity
600
定义原子立体中心数目
3
SMILES
O.Cl.C1=CC=C([C@H](C(N[C@@H]2C(=O)N3C(=C(CS[C@H]23)C)C(=O)O)=O)N)C=C1
InChi Key
YHJDZIQOCSDIQU-OEDJVVDHSA-N
InChi Code
InChI=1S/C16H17N3O4S.ClH.H2O/c1-8-7-24-15-11(14(21)19(15)12(8)16(22)23)18-13(20)10(17)9-5-3-2-4-6-9;;/h2-6,10-11,15H,7,17H2,1H3,(H,18,20)(H,22,23);1H;1H2/t10-,11-,15-;;/m1../s1
化学名
(6R,7R)-7-[[(2R)-2-amino-2-phenylacetyl]amino]-3-methyl-8-oxo-5-thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylic acid;hydrate;hydrochloride
别名
Cephalexin hydrochloride; Keftab; Cephalexin HCl; 105879-42-3; Cefalexin hydrochloride; LY061188; UNII-6VJE5G3D98; 6VJE5G3D98;
HS Tariff Code
2934.99.9001
存储方式

Powder      -20°C    3 years

                     4°C     2 years

In solvent   -80°C    6 months

                  -20°C    1 month
运输条件
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
溶解度数据
溶解度 (体外实验)
May dissolve in DMSO (in most cases), if not, try other solvents such as H2O, Ethanol, or DMF with a minute amount of products to avoid loss of samples
溶解度 (体内实验)
注意: 如下所列的是一些常用的体内动物实验溶解配方，主要用于溶解难溶或不溶于水的产品（水溶度<1 mg/mL）。 建议您先取少量样品进行尝试，如该配方可行，再根据实验需求增加样品量。
注射用配方
(IP/IV/IM/SC等)
注射用配方1: DMSO : Tween 80： Saline = 10 : 5 : 85 (如： 100 μL DMSO → 50 μL Tween 80 → 850 μL Saline)
*生理盐水/Saline的制备：将0.9g氯化钠/NaCl溶解在100 mL ddH ₂ O中，得到澄清溶液。
注射用配方 2: DMSO : PEG300 ：Tween 80 : Saline = 10 : 40 : 5 : 45 (如： 100 μL DMSO → 400 μL PEG300 → 50 μL Tween 80 → 450 μL Saline)
注射用配方 3: DMSO : Corn oil = 10 : 90 (如： 100 μL DMSO → 900 μL Corn oil)
示例: 以注射用配方 3 (DMSO : Corn oil = 10 : 90) 为例说明, 如果要配制 1 mL 2.5 mg/mL的工作液, 您可以取 100 μL 25 mg/mL 澄清的 DMSO 储备液，加到 900 μL Corn oil/玉米油中, 混合均匀。
View More

注射用配方 4: DMSO : 20% SBE-β-CD in Saline = 10 : 90 [如：100 μL DMSO → 900 μL (20% SBE-β-CD in Saline)]
*20% SBE-β-CD in Saline的制备（4°C，储存1周）：将2g SBE-β-CD (磺丁基-β-环糊精) 溶解于10mL生理盐水中，得到澄清溶液。
注射用配方 5: 2-Hydroxypropyl-β-cyclodextrin : Saline = 50 : 50 (如： 500 μL 2-Hydroxypropyl-β-cyclodextrin (羟丙基环胡精)→ 500 μL Saline)
注射用配方 6: DMSO : PEG300 : Castor oil : Saline = 5 : 10 : 20 : 65 (如： 50 μL DMSO → 100 μL PEG300 → 200 μL Castor oil → 650 μL Saline)
注射用配方 7: Ethanol : Cremophor : Saline = 10： 10 : 80 (如： 100 μL Ethanol → 100 μL Cremophor → 800 μL Saline)
注射用配方 8: 溶解于Cremophor/Ethanol (50 : 50), 然后用生理盐水稀释。
注射用配方 9: EtOH : Corn oil = 10 : 90 (如： 100 μL EtOH → 900 μL Corn oil)
注射用配方 10: EtOH : PEG300：Tween 80 : Saline = 10 : 40 : 5 : 45 (如： 100 μL EtOH → 400 μL PEG300 → 50 μL Tween 80 → 450 μL Saline)

口服配方
口服配方 1: 悬浮于0.5% CMC Na (羧甲基纤维素钠)
口服配方 2: 悬浮于0.5% Carboxymethyl cellulose (羧甲基纤维素)
示例: 以口服配方 1 (悬浮于 0.5% CMC Na)为例说明, 如果要配制 100 mL 2.5 mg/mL 的工作液, 您可以先取0.5g CMC Na并将其溶解于100mL ddH2O中，得到0.5%CMC-Na澄清溶液；然后将250 mg待测化合物加到100 mL前述 0.5%CMC Na溶液中，得到悬浮液。
View More

口服配方 3: 溶解于 PEG400 (聚乙二醇400)
口服配方 4: 悬浮于0.2% Carboxymethyl cellulose (羧甲基纤维素)
口服配方 5: 溶解于0.25% Tween 80 and 0.5% Carboxymethyl cellulose (羧甲基纤维素)
口服配方 6: 做成粉末与食物混合

注意: 以上为较为常见方法，仅供参考， InvivoChem并未独立验证这些配方的准确性。具体溶剂的选择首先应参照文献已报道溶解方法、配方或剂型，对于某些尚未有文献报道溶解方法的化合物，需通过前期实验来确定（建议先取少量样品进行尝试），包括产品的溶解情况、梯度设置、动物的耐受性等。
请根据您的实验动物和给药方式选择适当的溶解配方/方案：
1、请先配制澄清的储备液(如：用DMSO配置50 或 100 mg/mL母液(储备液));
2、取适量母液，按从左到右的顺序依次添加助溶剂，澄清后再加入下一助溶剂。以 下列配方为例说明 (注意此配方只用于说明，并不一定代表此产品 的实际溶解配方):
10% DMSO → 40% PEG300 → 5% Tween-80 → 45% ddH2O (或 saline);
假设最终工作液的体积为 1 mL, 浓度为5 mg/mL: 取 100 μL 50 mg/mL 的澄清 DMSO 储备液加到 400 μL PEG300 中，混合均匀/澄清；向上述体系中加入50 μL Tween-80，混合均匀/澄清；然后继续加入450 μL ddH2O (或 saline)定容至 1 mL；
3、溶剂前显示的百分比是指该溶剂在最终溶液/工作液中的体积所占比例;
4、 如产品在配制过程中出现沉淀/析出，可通过加热(≤50℃)或超声的方式助溶;
5、为保证最佳实验结果，工作液请现配现用！
6、如不确定怎么将母液配置成体内动物实验的工作液，请查看说明书或联系我们;
7、 以上所有助溶剂都可在 Invivochem.cn网站购买。
制备储备液 1 mg 5 mg 10 mg
1 mM 2.8786 mL 14.3930 mL 28.7861 mL
5 mM 0.5757 mL 2.8786 mL 5.7572 mL
10 mM 0.2879 mL 1.4393 mL 2.8786 mL

1、根据实验需要选择合适的溶剂配制储备液 (母液)：对于大多数产品，InvivoChem推荐用DMSO配置母液 (比如：5、10、20mM或者10、20、50 mg/mL浓度），个别水溶性高的产品可直接溶于水。产品在DMSO 、水或其他溶剂中的具体溶解度详见上”溶解度 (体外)”部分;

2、如果您找不到您想要的溶解度信息，或者很难将产品溶解在溶液中，请联系我们;

3、建议使用下列计算器进行相关计算（摩尔浓度计算器、稀释计算器、分子量计算器、重组计算器等）;

4、母液配好之后，将其分装到常规用量，并储存在-20°C或-80°C，尽量减少反复冻融循环。

计算器
计算 重置

摩尔浓度计算器可计算特定溶液所需的质量、体积/浓度，具体如下：

  • 计算制备已知体积和浓度的溶液所需的化合物的质量
  • 计算将已知质量的化合物溶解到所需浓度所需的溶液体积
  • 计算特定体积中已知质量的化合物产生的溶液的浓度
使用摩尔浓度计算器计算摩尔浓度的示例如下所示：
假如化合物的分子量为350.26 g/mol，在5mL DMSO中制备10mM储备液所需的化合物的质量是多少？
  • 在分子量（MW）框中输入350.26
  • 在“浓度”框中输入10，然后选择正确的单位（mM）
  • 在“体积”框中输入5，然后选择正确的单位（mL）
  • 单击“计算”按钮
  • 答案17.513 mg出现在“质量”框中。以类似的方式，您可以计算体积和浓度。
计算 重置

稀释计算器可计算如何稀释已知浓度的储备液。例如，可以输入C1、C2和V2来计算V1，具体如下：

制备25毫升25μM溶液需要多少体积的10 mM储备溶液？
使用方程式C1V1=C2V2，其中C1=10mM，C2=25μM，V2=25 ml，V1未知：
  • 在C1框中输入10，然后选择正确的单位（mM）
  • 在C2框中输入25，然后选择正确的单位（μM）
  • 在V2框中输入25，然后选择正确的单位（mL）
  • 单击“计算”按钮
  • 答案62.5μL（0.1 ml）出现在V1框中
g/mol
计算 重置

分子量计算器可计算化合物的分子量 (摩尔质量)和元素组成，具体如下：

注：化学分子式大小写敏感：C12H18N3O4  c12h18n3o4
计算化合物摩尔质量（分子量）的说明：
  • 要计算化合物的分子量 (摩尔质量)，请输入化学/分子式，然后单击“计算”按钮。
分子质量、分子量、摩尔质量和摩尔量的定义：
  • 分子质量（或分子量）是一种物质的一个分子的质量，用统一的原子质量单位（u）表示。（1u等于碳-12中一个原子质量的1/12）
  • 摩尔质量（摩尔重量）是一摩尔物质的质量，以g/mol表示。
/
计算 重置

配液计算器可计算将特定质量的产品配成特定浓度所需的溶剂体积 (配液体积)

  • 输入试剂的质量、所需的配液浓度以及正确的单位
  • 单击“计算”按钮
  • 答案显示在体积框中
动物体内实验配方计算器（澄清溶液）
第一步：请输入基本实验信息（考虑到实验过程中的损耗，建议多配一只动物的药量）
第二步：请输入动物体内配方组成（配方适用于不溶/难溶于水的化合物），不同的产品和批次配方组成不同，如对配方有疑问，可先联系我们提供正确的体内实验配方。此外，请注意这只是一个配方计算器，而不是特定产品的确切配方。
+
+
+
计算 重置

计算结果:

工作液浓度： mg/mL；

DMSO母液配制方法： mg 药物溶于 μL DMSO溶液（母液浓度 mg/mL)。如该浓度超过该批次药物DMSO溶解度，请首先与我们联系。

体内配方配制方法：取 μL DMSO母液，加入 μL PEG300，混匀澄清后加入μL Tween 80，混匀澄清后加入 μL ddH2O，混匀澄清。

(1) 请确保溶液澄清之后，再加入下一种溶剂 (助溶剂) 。可利用涡旋、超声或水浴加热等方法助溶；
            (2) 一定要按顺序加入溶剂 (助溶剂) 。

临床试验信息
High-dose Cephalexin for Cellulitis (HI-DOCC)
CTID: NCT05852262
Phase: Phase 4
Status: Enrolling by invitation
Date: 2024-09-23
Effects of Treatments on Atopic Dermatitis
CTID: NCT01631617
Phase: Phase 2
Status: Recruiting
Date: 2024-09-20
Utility of Single-dose Oral Antibiotic Prophylaxis in Prevention of Surgical Site Infection in Dermatologic Surgery
CTID: NCT04580472
Phase: Phase 4
Status: Recruiting
Date: 2024-08-22
Patient-Directed Antimicrobial Duration in Acute Uncomplicated Pyelonephritis
CTID: NCT06127160
Phase: Phase 4
Status: Recruiting
Date: 2024-08-09
Antibiotic Prophylaxis in High-Risk Arthroplasty Patients
CTID: NCT04297592
Phase: Phase 4
Status: Enrolling by invitation
Date: 2024-06-27
联系我们
电话: 020-31522723 QQ： 463611831 邮箱: sales@invivochem.cn
获得最新产品资讯、折扣和优惠
姓名
邮箱

InvivoChem的所有产品仅用于作科学研究，不面向患者销售

Copyright 2020 InvivoChem LLC | All Rights Reserved 粤ICP备20063088号-1

 粤公网安备 44011102003439号

联系我们
Home Classify Cart Member